Karuna Therapeutics Inc (KRTX)
$62.83 2.09 (3.22%)
12:01 EDT KRTX Stock Quote Delayed 20 Minutes
Previous Close $64.92
Market Cap -
PE Ratio -
Volume (Avg. Vol.) 64,612
Day's Range 62.00 - 65.92
52-Week Range 11.24 - 152.00
Dividend & Yield N/A (N/A)
KRTX Stock Predictions, Articles, and Karuna Therapeutics Inc News
- From InvestorPlace
- From the Web
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.
In just a matter of a single day, KRTX stock skyrocketed to triple-digit gains. However, Karuna Therapeutics remains a risky pharma play when all is said and done.
Almost immediately after Karuna Therapeutics (NASDAQ:KRTX) soared to $152, the company priced a public offering of its stock. So, after the cash raise torpedoed the....
Karuna Therapeutics (KRTX) news for Monday concerning a Phase 2 clinical trial of schizophrenia drug KarXT has KRTX stock soaring.
From Simply Wall St
Even when a business is losing money, it’s possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krtx/karuna-therapeutics/news/were-hopeful-that-karuna-therapeutics-nasdaqkrtx-will-use-its-cash-wisely/">Read More...</a></div>
From Analyst Ratings
Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Karuna Therapeutics (KRTX – Research Report) today and set a price target of $120.00. The company’s shares closed last Monday at $71.35. According to TipRanks.com, Divan is a 1-star analyst with an average return of -4.2% and a 39.7% success rate. Divan covers the Healthcare
From Seeking Alpha